This provider's $7.5M in total Medicare payments ranks in the 87th percentile of Clinical Laboratory providers nationally.
Medicare payments to this provider grew 695% from 2018 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 488% in 2022
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2018 | $1.4K | $107.00 | 12.79x | $1.3K | $411.1K | 3.8K | 8 |
| 2019 | $303.37 | $54.78 | 5.54x | $248.59 | $1.0M | 18.4K | 15 |
| 2020 | $225.28 | $48.29 | 4.67x | $176.99 | $469.5K | 9.7K | 14 |
| 2021 | $263.02 | $56.35 | 4.67x | $206.67 | $334.7K | 5.9K | 7 |
| 2022 | $181.28 | $53.79 | 3.37x | $127.49 | $2.0M | 36.6K | 6 |
| 2023 | $295.00 | $92.48 | 3.19x | $202.52 | $3.3M | 35.4K | 5 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| 87636 | Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19) and influenza virus types a and b | 20.7K | $2.8M | $135.16 | 3.20x |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 19.0K | $1.4M | $74.20 | 3.29x |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 22.7K | $860.7K | $37.85 | 2.99x |
| 87150 | Identification of organisms by genetic analysis, amplified probe technique | 11.0K | $404.5K | $36.92 | 3.04x |
| 87801 | Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 4.8K | $359.7K | $74.18 | 3.13x |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | 10.6K | $261.3K | $24.69 | 3.84x |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 1.3K | $256.8K | $194.86 | 12.24x |
| 80307 | Testing for presence of drug, by chemistry analyzers | 2.9K | $195.0K | $66.54 | 15.29x |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 1.3K | $150.7K | $112.00 | 12.27x |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 761 | $116.5K | $153.15 | 12.28x |
| 87637 | Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | 584 | $76.0K | $130.17 | 3.60x |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.8K | $64.1K | $22.99 | 2.55x |
| 87481 | Detection test for candida species (yeast), amplified probe technique | 1.6K | $61.0K | $37.09 | 3.13x |
| 87633 | Detection test for multiple types of respiratory virus | 122 | $57.9K | $474.50 | 8.16x |
| 87798 | Detection test by nucleic acid for organism, amplified probe technique | 1.4K | $51.0K | $35.92 | 3.52x |
| 87551 | Detection test for mycobacteria species (bacteria) | 965 | $45.6K | $47.28 | 3.19x |
| 87640 | Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 1.1K | $42.5K | $36.93 | 3.07x |
| 87653 | Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 1.1K | $42.5K | $36.93 | 3.07x |
| 87651 | Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 1.1K | $42.4K | $36.93 | 3.07x |
| 87641 | Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 1.1K | $40.2K | $37.04 | 3.10x |
This provider submits charges 4.24 times higher than what Medicare actually pays.
A markup ratio of 4.24x means for every $100 Medicare pays, this provider initially charges $424. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in TX for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Clinical Pathology Laboratories, Inc. | Austin, TX | $541.0M | ⚠️ Flagged |
| Quest Diagnostics Clinical Laboratories Inc | Irving, TX | $453.2M | ⚠️ Flagged |
| Laboratory Corporation Of America | Dallas, TX | $389.6M | ⚠️ Flagged |
| Quest Diagnostics Clinical Laboratories Inc | Houston, TX | $311.2M | ⚠️ Flagged |
| Laboratory Corporation Of America | Houston, TX | $299.4M | ⚠️ Flagged |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data